Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Case Report
  • Published:

Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation

Bone Marrow Transplantation volume 26, pages 1243–1245 (2000)Cite this article

Abstract

Hepatitis B virus (HBV) can be a cause of fatal liver failure after chemotherapy for viral carrier patients and limits the indication of myeloablative therapy for them. We describe an HBsAg-positive leukemia patient who successfully underwent autologous PBSC transplant. After chemotherapeutic treatment his serum HBV DNA level rose in association with hepatitis. To prevent progression to fulminant hepatitis, we administered lamivudine, a viral reverse transcriptase inhibitor, during the transplantation procedure. The patient did not show any increase of HBV DNA or a worsening of his hepatitis. Thus, lamivudine may be a promising treatment for HBsAg-positive patients receiving myeloablative chemotherapy and autologous stem cell transplantation. Bone Marrow Transplantation (2000) 26, 1243–1245.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Lau GKK, Liang R, Chiu EKW et al. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study Bone Marrow Transplant 1997 19: 795–799

    Article  CAS  Google Scholar 

  2. Perrillo RP . Treatment of chronic hepatitis B with interferon: experience in Western countries Semin Liver Dis 1989 9: 240–248

    Article  CAS  Google Scholar 

  3. Doong SL, Tsai CH, Schinazi RF et al. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy-3′-thiacytidine and related analogues Proc Natl Acad Sci USA 1991 88: 8495–8499

    Article  CAS  Google Scholar 

  4. Lai CL, Chien RN, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B New Engl J Med 1998 339: 61–68

    Article  CAS  Google Scholar 

  5. Dienstag JL, Schiff ER, Wright TL et al. Lamivudine as initial treatment for chronic hepatitis B in the United States New Engl J Med 1999 341: 1256–1263

    Article  CAS  Google Scholar 

  6. Gondo H, Harada M, Miyamoto T et al. Autologous peripheral blood stem cell transplantation for acute myelogenous leukemia Bone Marrow Transplant 1997 20: 821–826

    Article  CAS  Google Scholar 

  7. Urdea MS, Horn T, Fultz TJ et al. Branched DNA amplification multimers for the sensitive, direct detection of human hepatitis viruses Nucleic Acids Symp Ser 1991 24: 197–200

    CAS  Google Scholar 

  8. Picardi M, Selleri C, De Rosa G et al. Lamivudine treatment for chronic replicative hepatitis B virus infection after allogeneic bone marrow transplantation Bone Marrow Transplant 1998 21: 1267–1269

    Article  CAS  Google Scholar 

  9. Clark FL, Drummond MW, Chambers S et al. Successful treatment with lamivudine for fulminant reactivated hepatitis B infection following intensive therapy for high-grade non-Hodgkin's lymphoma Ann Oncol 1998 9: 385–387

    Article  CAS  Google Scholar 

  10. Liaw YF, Chien RN, Yeh CT et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy Hepatology 1999 30: 567–572

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the Glaxo Wellcome Research and Development (Greenford, UK) for kindly providing lamivudine.

Author information

Authors and Affiliations

  1. First Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan

    N Uchida, H Gondo, D Himeji, Y Kaji & Y Niho

  2. Second Department of Internal Medicine, Faculty of Medicine, Kurume University, Fukuoka, Japan

    M Sata

Authors
  1. N Uchida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H Gondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D Himeji
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Kaji
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Sata
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Y Niho
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uchida, N., Gondo, H., Himeji, D. et al. Lamivudine therapy for a hepatitis B surface antigen (HBsAg)-positive leukemia patient receiving myeloablative chemotherapy and autologous stem cell transplantation. Bone Marrow Transplant 26, 1243–1245 (2000). https://doi.org/10.1038/sj.bmt.1702693

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702693

Keywords

This article is cited by

Search

Advanced search

Quick links